Annual SGA
$6.64 M
-$1.57 M-19.09%
March 1, 2024
Summary
- As of February 8, 2025, GRCE annual SGA is $6.64 million, with the most recent change of -$1.57 million (-19.09%) on March 1, 2024.
- During the last 3 years, GRCE annual SGA has fallen by -$11.00 thousand (-0.17%).
- GRCE annual SGA is now -32.07% below its all-time high of $9.78 million, reached on March 1, 2022.
Performance
GRCE SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$1.85 M
-$401.00 K-17.79%
September 1, 2024
Summary
- As of February 8, 2025, GRCE quarterly SGA is $1.85 million, with the most recent change of -$401.00 thousand (-17.79%) on September 1, 2024.
- Over the past year, GRCE quarterly SGA has increased by +$253.00 thousand (+15.81%).
- GRCE quarterly SGA is now -37.86% below its all-time high of $2.98 million, reached on September 1, 2021.
Performance
GRCE Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$849.98 M
-$11.61 M-1.38%
September 1, 2024
Summary
- As of February 8, 2025, GRCE TTM SGA is -$849.98 million, with the most recent change of -$11.61 million (-1.38%) on September 1, 2024.
- Over the past year, GRCE TTM SGA has dropped by -$857.59 million (-11257.47%).
- GRCE TTM SGA is now -7959.01% below its all-time high of -$10.55 million.
Performance
GRCE TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
GRCE Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -19.1% | +15.8% | -10000.0% |
| 3 y3 years | -0.2% | +1.4% | -10000.0% |
| 5 y5 years | +54.8% | -19.5% | -10000.0% |
GRCE Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -32.1% | at low | -26.4% | +20.1% | -42.8% | at low |
| 5 y | 5-year | -32.1% | +54.8% | -37.9% | +39.2% | -82.5% | at low |
| alltime | all time | -32.1% | +1526.0% | -37.9% | +253.0% | -7959.0% | at low |
Grace Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.85 M(-17.8%) | $7.25 M(+3.2%) |
| Jun 2024 | - | $2.25 M(+46.1%) | $7.03 M(+5.8%) |
| Mar 2024 | $6.64 M(-19.1%) | $1.54 M(-3.6%) | $6.64 M(-12.8%) |
| Dec 2023 | - | $1.60 M(-1.9%) | $7.62 M(-2.2%) |
| Sep 2023 | - | $1.63 M(-12.8%) | $7.79 M(-2.5%) |
| Jun 2023 | - | $1.87 M(-25.6%) | $7.99 M(-2.7%) |
| Mar 2023 | $8.21 M(-16.0%) | $2.52 M(+41.7%) | $8.21 M(+5.6%) |
| Dec 2022 | - | $1.77 M(-2.9%) | $7.77 M(-3.4%) |
| Sep 2022 | - | $1.83 M(-12.7%) | $8.04 M(-12.5%) |
| Jun 2022 | - | $2.09 M(+0.8%) | $9.20 M(-6.0%) |
| Mar 2022 | $9.78 M(+47.0%) | $2.08 M(+1.5%) | $9.78 M(+6.2%) |
| Dec 2021 | - | $2.05 M(-31.4%) | $9.21 M(+8.4%) |
| Sep 2021 | - | $2.98 M(+11.4%) | $8.50 M(+21.9%) |
| Jun 2021 | - | $2.68 M(+77.3%) | $6.97 M(+4.7%) |
| Mar 2021 | $6.66 M(-21.4%) | $1.51 M(+13.4%) | $6.66 M(-8.3%) |
| Dec 2020 | - | $1.33 M(-8.4%) | $7.26 M(-11.1%) |
| Sep 2020 | - | $1.45 M(-38.6%) | $8.16 M(-9.4%) |
| Jun 2020 | - | $2.37 M(+11.9%) | $9.01 M(+6.5%) |
| Mar 2020 | $8.46 M(+97.2%) | $2.11 M(-5.4%) | $8.46 M(+4.8%) |
| Dec 2019 | - | $2.23 M(-2.9%) | $8.07 M(+20.7%) |
| Sep 2019 | - | $2.30 M(+26.7%) | $6.69 M(+23.8%) |
| Jun 2019 | - | $1.82 M(+5.4%) | $5.40 M(+23.5%) |
| Mar 2019 | $4.29 M(+37.6%) | $1.72 M(+103.3%) | $4.37 M(+21.2%) |
| Dec 2018 | - | $847.30 K(-16.4%) | $3.61 M(+4.6%) |
| Sep 2018 | - | $1.01 M(+28.7%) | $3.45 M(+5.5%) |
| Jun 2018 | - | $787.70 K(-17.7%) | $3.27 M(+5.1%) |
| Mar 2018 | $3.12 M(+16.9%) | $956.90 K(+39.1%) | $3.11 M(+44.5%) |
| Dec 2017 | - | $687.90 K(-17.6%) | $2.15 M(+3.4%) |
| Sep 2017 | - | $835.10 K(+32.9%) | $2.08 M(+9.5%) |
| Jun 2017 | - | $628.20 K(+1.8%) | $1.90 M(-5.4%) |
| Mar 2017 | $2.67 M | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Nov 2016 | - | $617.00 K(-5.6%) | $2.01 M(+14.7%) |
| Aug 2016 | - | $653.90 K(+50.7%) | $1.75 M(+18.6%) |
| May 2016 | - | $434.00 K(+43.7%) | $1.48 M(-4.8%) |
| Feb 2016 | $1.51 M(-47.1%) | $302.00 K(-16.0%) | $1.55 M(+4156.3%) |
| Nov 2015 | - | $359.70 K(-5.2%) | $36.40 K(-95.1%) |
| Aug 2015 | - | $379.60 K(-25.3%) | $742.60 K(-60.6%) |
| May 2015 | - | $508.00 K(-142.0%) | $1.89 M(-37.6%) |
| Feb 2015 | $2.86 M(-35.8%) | -$1.21 M(-213.6%) | $3.02 M(-22.1%) |
| Nov 2014 | - | $1.07 M(-30.0%) | $3.88 M(-18.2%) |
| Aug 2014 | - | $1.52 M(-7.3%) | $4.74 M(-4.6%) |
| May 2014 | - | $1.64 M(-564.4%) | $4.97 M(+10.6%) |
| Feb 2014 | $4.45 M(+6.2%) | -$353.60 K(-118.3%) | $4.49 M(-22.7%) |
| Nov 2013 | - | $1.93 M(+10.0%) | $5.81 M(+17.9%) |
| Aug 2013 | - | $1.75 M(+50.1%) | $4.93 M(+15.2%) |
| May 2013 | - | $1.17 M(+20.9%) | $4.28 M(+3.1%) |
| Feb 2013 | $4.19 M(+18.0%) | $965.80 K(-7.7%) | $4.15 M(-6.8%) |
| Nov 2012 | - | $1.05 M(-5.1%) | $4.45 M(+5.3%) |
| Aug 2012 | - | $1.10 M(+6.2%) | $4.23 M(+5.7%) |
| May 2012 | - | $1.04 M(-18.3%) | $4.00 M(+10.5%) |
| Feb 2012 | $3.55 M(+115.8%) | $1.27 M(+54.1%) | $3.62 M(+22.7%) |
| Nov 2011 | - | $823.50 K(-5.7%) | $2.95 M(+15.6%) |
| Aug 2011 | - | $873.60 K(+33.2%) | $2.55 M(+27.7%) |
| May 2011 | - | $655.90 K(+9.6%) | $2.00 M(+23.3%) |
| Feb 2011 | $1.64 M(+302.6%) | $598.30 K(+40.8%) | $1.62 M(+38.5%) |
| Nov 2010 | - | $424.80 K(+32.5%) | $1.17 M(+38.8%) |
| Aug 2010 | - | $320.50 K(+15.0%) | $843.80 K(+35.9%) |
| May 2010 | - | $278.70 K(+89.6%) | $620.80 K(+53.9%) |
| Feb 2010 | $408.60 K | $147.00 K(+50.6%) | $403.30 K(+57.4%) |
| Nov 2009 | - | $97.60 K(+0.1%) | $256.30 K(+0.3%) |
| Aug 2009 | - | $97.50 K(+59.3%) | $255.60 K(+61.7%) |
| May 2009 | - | $61.20 K(-36.8%) | $158.10 K(+63.2%) |
| Nov 2008 | - | $96.90 K | $96.90 K |
FAQ
- What is Grace Therapeutics annual SGA?
- What is the all time high annual SGA for Grace Therapeutics?
- What is Grace Therapeutics annual SGA year-on-year change?
- What is Grace Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Grace Therapeutics?
- What is Grace Therapeutics quarterly SGA year-on-year change?
- What is Grace Therapeutics TTM SGA?
- What is the all time high TTM SGA for Grace Therapeutics?
- What is Grace Therapeutics TTM SGA year-on-year change?
What is Grace Therapeutics annual SGA?
The current annual SGA of GRCE is $6.64 M
What is the all time high annual SGA for Grace Therapeutics?
Grace Therapeutics all-time high annual SGA is $9.78 M
What is Grace Therapeutics annual SGA year-on-year change?
Over the past year, GRCE annual SGA has changed by -$1.57 M (-19.09%)
What is Grace Therapeutics quarterly SGA?
The current quarterly SGA of GRCE is $1.85 M
What is the all time high quarterly SGA for Grace Therapeutics?
Grace Therapeutics all-time high quarterly SGA is $2.98 M
What is Grace Therapeutics quarterly SGA year-on-year change?
Over the past year, GRCE quarterly SGA has changed by +$253.00 K (+15.81%)
What is Grace Therapeutics TTM SGA?
The current TTM SGA of GRCE is -$849.98 M
What is the all time high TTM SGA for Grace Therapeutics?
Grace Therapeutics all-time high TTM SGA is -$10.55 M
What is Grace Therapeutics TTM SGA year-on-year change?
Over the past year, GRCE TTM SGA has changed by -$857.59 M (-11257.47%)